Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 19.5 mg intrauterine system (IUS) for intrauterine use. It provides long‑acting hormonal contraception for women of reproductive age, preventing pregnancy by inhibiting ovulation and altering cervical mucus and endometrium.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets. The company provides reliable logistics and documentation for cross‑border procurement.

Kyleena, a levonorgestrel intrauterine system, is used in hormonal contraception to provide long‑acting reversible birth control.

Contraception (prevention of pregnancy): provides highly effective, reversible birth control for women of reproductive age. Long‑acting reversible contraception (LARC): delivers continuous levonorgestrel release for up to five years. Reduction of menstrual bleeding: can lessen menstrual flow and related symptoms in many users.

Kyleena may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Cramps or pelvic pain - Headache - Breast tenderness

Serious or Rare Side Effects: - Uterine perforation - Expulsion of the device - Pelvic inflammatory disease (PID)

When prescribing Kyleena, clinicians should consider several precautionary measures to ensure safe use.

Screen for pregnancy: confirm patient is not pregnant before insertion. Assess uterine abnormalities: evaluate for fibroids, congenital anomalies, or active infection. Consider hormonal sensitivity: discuss potential side effects with patients having a history of hormone‑related disorders. Monitor for device displacement: schedule follow‑up visits to confirm correct positioning. Store at room temperature: keep the device in its original packaging, protect from moisture and extreme heat.

Levonorgestrel IUS may interact with other agents that affect hormonal balance or uterine environment.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce levonorgestrel efficacy. - Rifampin or other strong CYP3A4 inducers: can lower hormone levels.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase levonorgestrel exposure. - Antiretroviral therapy (e.g., protease inhibitors): potential pharmacokinetic changes. - Herbal supplements containing St. John’s wort: may modestly decrease effectiveness.